How satisfied are patients with a new way to take MS medication?

This study follows people with multiple sclerosis who are starting ocrelizumab as a new subcutaneous injection (a shot under the skin) for the first time. Researchers want to understand how satisfied patients are with this new way of receiving the medication and track whether it affects a marker in the blood called neurofilament light chain, which can indicate nerve damage. Over 12 months, participants will answer surveys about their experience with the treatment.

Ocrelizumab is now available as a subcutaneous injection instead of only as an infusion in a clinic. This study exists to understand whether patients prefer this new, easier method of administration and whether it affects nerve health markers the same way the older form of the medication does.